Clinical trial registry record

Phase III Trial of Sirolimus in IBM

A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Active Not Recruiting.
Evidence
Registered phase 3 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated January 14, 2026.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT04789070
Last registry update
January 14, 2026
Status
Active Not Recruiting
Phase
Phase 3
Sponsor
University of Kansas Medical Center
Enrollment
140
Countries
United States, Australia, Netherlands
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 3
Study design
RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE
Evidence population
Human clinical study registration
Participants
140
Population
ALL · 45 Years
Duration
2022-07-01 to 2027-12-01
Intervention
Sirolimus; Placebo
Comparator
Sirolimus; Placebo
Outcomes measured
Change in IBM Functional Rating Scale (IBM-FRS) from Baseline to Week 84 — Baseline, Week 84; Change in 6 Minute Walk Test (6MWT) from Baseline to Week 84 — Baseline, Week 84; Change in Modified Timed Up and Go (mTUG) from Baseline to Week 84 — Baseline, Week 84; Change in Manual Muscle Testing (MMT) from Baseline to Week 84 — Baseline, Week 84
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 3A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Rapamycin · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Source terminology contains a controlled topic term.

Automated source check 100% · update recency 85%. These figures help sort records; they are not medical ratings.

rapamycin
Read the original source →Export JSON